JP2024516962A - 安定性が改善された抗ＴＳＬＰ Ｆａｂ - Google Patents

安定性が改善された抗ＴＳＬＰ Ｆａｂ Download PDF

Info

Publication number
JP2024516962A
JP2024516962A JP2023563876A JP2023563876A JP2024516962A JP 2024516962 A JP2024516962 A JP 2024516962A JP 2023563876 A JP2023563876 A JP 2023563876A JP 2023563876 A JP2023563876 A JP 2023563876A JP 2024516962 A JP2024516962 A JP 2024516962A
Authority
JP
Japan
Prior art keywords
fab
tslp
cells
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023563876A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516962A5 (https=
Inventor
ウィルヘルム コルベック，ローランド
スザンヌ コーエン，エマ
ユージェニー ハンティントン，キャサリン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2024516962A publication Critical patent/JP2024516962A/ja
Publication of JP2024516962A5 publication Critical patent/JP2024516962A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023563876A 2021-04-19 2022-04-19 安定性が改善された抗ＴＳＬＰ Ｆａｂ Pending JP2024516962A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21169183 2021-04-19
EP21169183.7 2021-04-19
PCT/EP2022/060236 WO2022223514A1 (en) 2021-04-19 2022-04-19 An anti-tslp fab with improved stability

Publications (2)

Publication Number Publication Date
JP2024516962A true JP2024516962A (ja) 2024-04-18
JP2024516962A5 JP2024516962A5 (https=) 2025-05-16

Family

ID=75588042

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023563876A Pending JP2024516962A (ja) 2021-04-19 2022-04-19 安定性が改善された抗ＴＳＬＰ Ｆａｂ

Country Status (19)

Country Link
US (1) US20240199730A1 (https=)
EP (1) EP4326767A1 (https=)
JP (1) JP2024516962A (https=)
KR (1) KR20230172508A (https=)
CN (1) CN117222665A (https=)
AR (1) AR125379A1 (https=)
AU (1) AU2022263281A1 (https=)
BR (1) BR112023021587A2 (https=)
CA (1) CA3216894A1 (https=)
CL (1) CL2023003082A1 (https=)
CO (1) CO2023015286A2 (https=)
CR (1) CR20230533A (https=)
EC (1) ECSP23086870A (https=)
IL (1) IL307651A (https=)
MX (1) MX2023012266A (https=)
PH (1) PH12023552762A1 (https=)
SA (1) SA523451188B1 (https=)
TW (1) TW202306982A (https=)
WO (1) WO2022223514A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022551022A1 (en) * 2019-10-28 2023-03-06 Medimmune Ltd Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
TW202529811A (zh) 2024-01-29 2025-08-01 瑞典商阿斯特捷利康公司 胸腺基質淋巴細胞生成素（ｔｓｌｐ）結合片段之組成物及其使用方法
US20260034317A1 (en) 2024-05-20 2026-02-05 Medimmune Limited Inhaler and capsule for delivering thymic stromal lymphopoietin (tslp)-binding antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018191479A1 (en) * 2017-04-12 2018-10-18 Amgen Inc. Treatment of asthma with anti-tslp antibody
WO2021043221A1 (en) * 2019-09-04 2021-03-11 Biosion Inc. Antibodies binding tslp and uses thereof
JP2022554249A (ja) * 2019-10-28 2022-12-28 メドイミューン・リミテッド 胸腺間質性リンパ球新生因子（ｔｓｌｐ）結合抗体の乾燥粉末製剤及びその使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001297872B2 (en) 2000-11-17 2006-11-09 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018191479A1 (en) * 2017-04-12 2018-10-18 Amgen Inc. Treatment of asthma with anti-tslp antibody
WO2021043221A1 (en) * 2019-09-04 2021-03-11 Biosion Inc. Antibodies binding tslp and uses thereof
JP2022554249A (ja) * 2019-10-28 2022-12-28 メドイミューン・リミテッド 胸腺間質性リンパ球新生因子（ｔｓｌｐ）結合抗体の乾燥粉末製剤及びその使用方法

Also Published As

Publication number Publication date
MX2023012266A (es) 2023-10-24
TW202306982A (zh) 2023-02-16
CL2023003082A1 (es) 2024-04-19
EP4326767A1 (en) 2024-02-28
CN117222665A (zh) 2023-12-12
CO2023015286A2 (es) 2024-02-05
BR112023021587A2 (pt) 2023-12-19
SA523451188B1 (ar) 2025-06-22
KR20230172508A (ko) 2023-12-22
AR125379A1 (es) 2023-07-12
CA3216894A1 (en) 2022-10-27
AU2022263281A9 (en) 2023-11-16
CR20230533A (es) 2024-04-05
IL307651A (en) 2023-12-01
PH12023552762A1 (en) 2024-04-15
AU2022263281A1 (en) 2023-11-09
US20240199730A1 (en) 2024-06-20
ECSP23086870A (es) 2023-12-29
WO2022223514A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
KR102330596B1 (ko) 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
US20240199730A1 (en) An anti-tslp fab with improved stability
CN105026428B (zh) PD‑l抗体、其抗原结合片段及其医药用途
EP4289861A1 (en) Antibodies against human tslp and use thereof
JP4336376B2 (ja) 延長した半減期を有する分子ならびにその組成物および用途
US11673950B2 (en) ILT7 binding molecules and methods of using the same
KR101824512B1 (ko) 과립구-대식세포 콜로니 자극 인자에 대한 항체
TW201206955A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
CN112654640B (zh) 抗IL-1β的抗体、其药物组合物及其用途
CN108473568A (zh) 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子
CN103974975A (zh) 抗假单胞菌Psl结合分子及其用途
CN114907479B (zh) 抗cd112r抗体及其用途
AU2020288749A1 (en) Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody
CN116574189A (zh) 针对人il-36r和/或人il-1r3的多种抗体及其用途
WO2022127842A1 (zh) 靶向il-17a和il-36r的双特异性抗体及其应用
EA052142B1 (ru) Fab К TSLP С ПОВЫШЕННОЙ СТАБИЛЬНОСТЬЮ
JP5476310B2 (ja) ｈＧＭ−ＣＳＦに結合するモノクローナル抗体および前記抗体を含む医薬組成物
RU2825460C1 (ru) Антитела к TSLP человека и их применение
CN119192370A (zh) 一种il-5结合分子及其应用
CN115340604A (zh) Tim-3全人源单克隆抗体及其应用
KR20210145187A (ko) Il-5에 대한 항체를 함유하는 약학적 조성물 및 이의 용도
JP2012105657A (ja) ｈＧＭ−ＣＳＦに結合するモノクローナル抗体および前記抗体を含む医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260224